quinaldine red: amphiphilic in cationic form; RN given refers to iodide; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 5702759 |
| CHEMBL ID | 1492585 |
| SCHEMBL ID | 124471 |
| MeSH ID | M0076037 |
| Synonym |
|---|
| HMS2565C04 |
| 117-92-0 |
| 1-ethyl-2-p-dimethylaminostyrylquinoline iodide |
| quinaldine red |
| eastman 1361 |
| nsc36339 |
| .alpha.-(p-dimethylaminophenylethylene)quinoline ethiodide |
| nsc-36339 |
| 2-(p-dimethylaminostyryl)quinoline ethiodide |
| MLS002637211 |
| nsc 36339 |
| Q0007 |
| AKOS001028487 |
| unii-z70656t34n |
| quinolinium, 2-(2-(4-(dimethylamino)phenyl)ethenyl)-1-ethyl-, iodide (1:1) |
| z70656t34n , |
| einecs 204-221-5 |
| 2-(2-(4-(dimethylamino)phenyl)ethenyl)-1-ethylquinolinium, iodide |
| quinolinium, 2-(2-(4-(dimethylamino)phenyl)ethenyl)-1-ethyl-, iodide |
| quinolinium, 2-(p-(dimethylamino)styryl)-1-ethyl-, iodide |
| 2-(-(4-dimethylamino)styryl)-1-ethylquinolinium iodide |
| alpha-(p-dimethylaminophenylethylene)quinolineethiodide |
| BP-12333 |
| REGID_FOR_CID_5702759 |
| 2-{2-[4-(dimethylamino)phenyl]ethenyl}-1-ethylquinolin-1-ium iodide |
| quinaldine red [mi] |
| 2-(2-(4-(dimethylamino)phenyl)ethenyl)-1-ethylquinolinium, e-, iodide (1:1) |
| CHEMBL1492585 |
| SCHEMBL124471 |
| W-108556 |
| 2-[4-(dimethylamino)styryl]-1-ethylquinolinium iodide |
| 2-(4-dimethylaminostyryl)-1-ethylquinolinium iodide |
| mfcd00011968 |
| 2-[2-[4-(dimethylamino)phenyl]ethenyl]-1-ethyl-quinoliniuiodide |
| AS-73150 |
| chinaldinrot |
| (e)-2-(4-(dimethylamino)styryl)-1-ethylquinolin-1-ium iodide |
| (e)-2-(4-(dimethylamino)styryl)-1-ethylquinolinium iodide |
| 190437-26-4 |
| 2,3-bis(acetyloxy)-3-(1,3-benzothiazol-2-yl)propanoicacid |
| 2-(4-(dimethylamino)styryl)-1-ethylquinolin-1-ium iodide |
| quinolinium, 2-[2-[4-(dimethylamino)phenyl]ethenyl]-1-ethyl-, iodide (1:1) |
| A853198 |
| 2-[(1e)-2-[4-(dimethylamino)phenyl]ethenyl]-1-ethylquinolin-1-ium iodide |
| EN300-21037300 |
| Z56758419 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 1.4125 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 70.7946 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 50.1187 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 26.8545 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| luteinizing hormone receptor | Homo sapiens (human) | Potency | 239.3410 | 23.9341 | 30.6323 | 37.9330 | AID602293 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 1.0000 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| WRN | Homo sapiens (human) | Potency | 28.1838 | 0.1683 | 31.2583 | 100.0000 | AID651768 |
| chaperonin-containing TCP-1 beta subunit homolog | Homo sapiens (human) | Potency | 141.2540 | 3.9811 | 27.7649 | 39.8107 | AID504842 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 12.5893 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
| TDP1 protein | Homo sapiens (human) | Potency | 0.1547 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| TSHR protein | Homo sapiens (human) | Potency | 314.0262 | 0.3381 | 19.0466 | 37.9330 | AID602292; AID602441 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 44.6684 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
| Smad3 | Homo sapiens (human) | Potency | 3.5481 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 14.1254 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 0.8913 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| PINK1 | Homo sapiens (human) | Potency | 0.4467 | 2.8184 | 18.8959 | 44.6684 | AID624263 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 28.1838 | 0.2239 | 11.2451 | 35.4813 | AID624173 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 19.9526 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
| 67.9K protein | Vaccinia virus | Potency | 13.3573 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
| luciferase | Photuris pensylvanica (Pennsylania firefly) | Potency | 8.9125 | 0.8913 | 10.4328 | 20.5750 | AID1379 |
| Parkin | Homo sapiens (human) | Potency | 0.4467 | 0.8199 | 14.8306 | 44.6684 | AID624263 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 39.8107 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| pyruvate kinase | Leishmania mexicana mexicana | Potency | 15.8489 | 0.3981 | 13.7447 | 31.6228 | AID1721; AID1722 |
| IDH1 | Homo sapiens (human) | Potency | 10.3225 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 14.1254 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 28.1838 | 0.5406 | 17.6392 | 96.1227 | AID2528 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 8.9125 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 8.1995 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 35.4813 | 0.7943 | 21.2757 | 50.1187 | AID624246 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 22.3872 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 28.1838 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 50.1187 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 0.7943 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 31.6228 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 3.3727 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 28.1838 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
| geminin | Homo sapiens (human) | Potency | 29.0929 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| Vpr | Human immunodeficiency virus 1 | Potency | 12.5893 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 1.2589 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 3.9811 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 1.4125 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 5.0119 | 0.0158 | 12.3113 | 615.5000 | AID1461 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 70.7946 | 6.3096 | 60.2008 | 112.2020 | AID720709 |
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 0.5623 | 15.1609 | 31.6228 | AID1721 |
| Endothelin-1 receptor | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 0.5623 | 15.1609 | 31.6228 | AID1721 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 10.0000 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 25.1189 | 1.9953 | 25.5327 | 50.1187 | AID624288 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 4.4668 | 1.0000 | 10.4756 | 28.1838 | AID1457 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 12.5893 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 79.4328 | 3.9811 | 46.7448 | 112.2020 | AID720708 |
| phosphoglycerate kinase | Trypanosoma brucei brucei TREU927 | Potency | 11.2202 | 0.0757 | 8.4742 | 29.0628 | AID602233 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| nonstructural protein 1 | Influenza A virus (A/California/07/2009(H1N1)) | IC50 (µMol) | 18.9190 | 0.2000 | 24.4540 | 100.0000 | AID504329 |
| rac GTPase-activating protein 1 isoform a | Homo sapiens (human) | IC50 (µMol) | 46.5800 | 7.3900 | 57.8904 | 301.2400 | AID624330 |
| M17 leucyl aminopeptidase | Plasmodium falciparum 3D7 | IC50 (µMol) | 110.2200 | 1.0000 | 27.8360 | 138.0800 | AID1619 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| POsterior Segregation | Caenorhabditis elegans | EC50 (µMol) | 300.0000 | 2.2010 | 47.1808 | 186.6810 | AID1964 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | EC50 (µMol) | 300.0000 | 0.0820 | 31.0243 | 168.9080 | AID1960 |
| Zinc finger protein mex-5 | Caenorhabditis elegans | EC50 (µMol) | 300.0000 | 0.0820 | 33.5679 | 168.9080 | AID1960 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| protein AF-9 isoform a | Homo sapiens (human) | AC50 | 8.2800 | 0.0800 | 8.3802 | 17.9800 | AID720495 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (32.04) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||